Site-Selective Antibody Conjugation with Dibromopyrazines

Area of Science:

• Bioconjugation Chemistry
• Antibody Engineering
• Drug Development

Background:

• Antibody conjugates are crucial for diagnostics and therapeutics.
• Current site-selective conjugation methods face challenges with incomplete antibody chain rebridging, leading to heterogeneous products.
• Novel rebridging agents are needed to improve conjugate homogeneity and efficiency.

Purpose of the Study:

• To develop and optimize a novel dibromopyrazine derivative as a rebridging agent for site-selective antibody conjugation.
• To assess the agent's efficiency, homogeneity, and applicability under various conditions, including acidic environments.
• To demonstrate the utility of the developed agent in creating functional antibody conjugates for diagnostic and therapeutic purposes.

Main Methods:

• Synthesis and optimization of a dibromopyrazine derivative.
• Site-selective conjugation of trastuzumab using the developed rebridging agent.
• Coupling of a fluorescent dye and a cytotoxic drug to the antibody.
• Evaluation of conjugate homogeneity, serum stability, and in vitro selectivity.

Main Results:

• The dibromopyrazine derivative achieved rapid and highly homogeneous antibody conjugates with high conversion rates.
• Effective antibody modification was feasible even under acidic conditions.
• Resulting antibody conjugates, loaded with dyes or drugs, exhibited excellent serum stability and in vitro selectivity.

Conclusions:

• The novel dibromopyrazine rebridging agent significantly enhances the homogeneity and efficiency of antibody conjugation.
• This agent offers a versatile platform for producing customized antibody conjugates under diverse conditions.
• The developed methodology holds promise for the on-demand creation of advanced antibody conjugates for future diagnostic and therapeutic applications.